Notably, Kang et al. [77] demonstrated in human NSCLC that trametinib (MEK1/2 inhibitor) enhances MHC-class I expression via signal transducer and activator of transcription-3 (STAT3) activation and upregulates chemokines associated with T cell infiltration and homing. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.